#1927 Clinical characteristics and healthcare resource utilization, and costs associated in patients with diagnosed and undetected hyperkalemia: IBERIK+ study
Rattachement africain : es. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background and Aims Hyperkalemia (HK) is a common complication of chronic kidney disease (CKD) and heart failure (HF), particularly among patients receiving renin-angiotensin-aldosterone system inhibitors (RAASi). This study aimed to describe the clinical characteristics and healthcare resource utilization (HCRU) and costs associated in patients with HK, differentiating between diagnosed and undetected HK cases in Spain. Method A descriptive, retrospective study conducted using the BIG-PAC database with Python technology in Spain. Patients with relevant diagnosis codes and/or treatments for HK and/or potassium values >5.0 mmol/L recorded in their medical history between January 2013-December 2020, with at least 2 years of follow-up, were included. The inclusion date was defined as the first HK event. HK event was considered undetected when diagnosis and/or treatment were not observed despite potassium >5.0 mmol/L at the index date. Baseline characteristics and HCRUs and cost associated were analyzed by diagnosed HK and undetected HK. Results A total of 7,006 patients (mean age: 66.9 ± 15.5 years; 52.0% women; mean BMI: 27.6 ± 4.8 kg/m2; mean eGFR: 38.1 ± 15.1 mL/min/1.73 m²; mean Charlson Comorbidity Index: 1.8 ± 2.0) were analyzed. Among them, only 33.5% were diagnosed with and/or treated for the HK event. Patients with undetected HK (66.5%) (vs diagnosed HK) were younger (66.1 vs 68.5 years), 58.7% had mild HK, 35.8% moderate HK, and 5.4% severe HK (vs 33.3% mild, 41,0% moderate and 25.6% severe) and less frequently experienced comorbid conditions (mean Charlson Comorbidity Index: 1.5 vs 2.5), though 62,4% presented at least one of the following comorbidities: HF (12.3% vs 36.2%), CKD (10.8% vs 42.4%), hypertension (51.0% vs 55.5%) or Type 2 diabetes (27.3% vs 28.5%). During the follow up period, HCRUs and annual costs per patient were higher in diagnosed HK than in initially undetected HK patients (Table 1). Conclusion Our data suggest that two-thirds of patients with HK events were undetected, including those with comorbid conditions and moderate-to-severe HK. Although clinical events, HCRU, and costs were higher in detected HK, they were also high among patients with undetected HK.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- #1927 Clinical characteristics and healthcare resource utilization, and costs associated in patients with diagnosed and undetected hyperkalemia: IBERIK+ study
- Date Crossref
- 01/10/2025
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
INCLIVA Health Research Institute pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario Infanta Leonor pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario 12 De Octubre pays non établi dans la noticeÉtablissement de santé
-
Universitat de Barcelona pays non établi dans la noticeUniversité ou école supérieure
-
AstraZeneca (Spain) pays non établi dans la noticeEntreprise
-
Hospital Universitario Fundación Jiménez Díaz pays non établi dans la noticeÉtablissement de santé
-
Universidad Autónoma de Madrid pays non établi dans la noticeUniversité ou école supérieure
-
Spain Department of Nephrology. Clinical University Hospital. University of València. INCLIVA Valencia pays non établi dans la noticeUniversité ou école supérieure
-
Spain Department of Nephrology. University Hospital Infanta Leonor. UCM. Madrid Madrid pays non établi dans la noticeUniversité ou école supérieure
-
Barcelona University Nephrology and Kidney Transplant Department. National Reference Center for Complex Glomerular Diseases (CSUR). Hospital Clínic pays non établi dans la noticeUniversité ou école supérieure
-
Employee at AstraZeneca Spain pays non établi dans la noticeInstitution
-
IIS-Fundacion Jimenez Diaz UAM pays non établi dans la noticeInstitution
INCLIVA Health Research Institute, Hospital Universitario Infanta Leonor et Hospital Universitario 12 De Octubre, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.